Sanofi’s bad, awful, terrible development week ends with PhIII C. diff failure

Friday marks the end of Sanofi’s bad, awful, terrible week of vaccine development news.

The pharma giant $SNY says it will terminate its late-stage program for a Clostridium difficile vaccine after investigators determined they were on a straight path to failure.

The setback follows fast on the news that Sanofi has conceded that its one-time ‘blockbuster’ dengue vaccine was dangerous when given to anyone who had not yet experienced an infection. Sanofi wrote off $120 million on a program it once reckoned was worth more than $1 billion a year.

The latest blow is good news for Pfizer $PFE, which has a C. diff vaccine of its own — PF-06425090, which stimulates an antibody response against two main toxins —  in hot pursuit.

Credit Suisse had estimated Sanofi’s vaccine could be worth more than $500 million a year in peak sales.

In a terse statement late Friday, Sanofi noted:

Sanofi Pasteur, the vaccines business of Sanofi responsible for the program, is informing all investigators, regulatory authorities and trial ethics committees. In addition, investigators are notifying study volunteers of the decision to stop the program.  Data from all vaccinated volunteers in this trial will continue to be analyzed for more information and shared with the scientific community.

Image: Shutterstock

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 31,600+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Rational Combinations 360

The UK Biopharma Research & Development Summit

Data Architect/Engineer
Camp4 Therapeutics Cambridge, MA
Chief Medical Officer
Skyhawk Therapeutics Waltham, MA
Chief of Staff, North America
Ipsen Biopharmaceuticals Cambridge, MA
Senior Director, NA Digital Customer Interaction
Ipsen Biopharmaceuticals Cambridge, MA

Visit Endpoints Careers ->